Your browser doesn't support javascript.
loading
A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis.
Sarkar, Reith R; Fero, Katherine E; Seible, Daniel M; Panjwani, Neil; Matsuno, Rayna K; Murphy, James D.
Afiliação
  • Sarkar RR; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.
  • Fero KE; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.
  • Seible DM; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.
  • Panjwani N; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.
  • Matsuno RK; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.
J Natl Compr Canc Netw ; 17(5): 432-440, 2019 05 01.
Article em En | MEDLINE | ID: mdl-31085756
ABSTRACT

BACKGROUND:

Pancreatic cancer is an aggressive disease characterized by early and relentless tumor spread, thus leading healthcare providers to consider it a "distant disease." However, local pancreatic tumor progression can lead to substantial morbidity. This study defines the long-term morbidity from local and nonlocal disease progression in a large population-based cohort.

METHODS:

A total of 21,500 Medicare beneficiaries diagnosed with pancreatic cancer in 2000 through 2011 were identified. Hospitalizations were attributed to complications of either local disease (eg, biliary disorder, upper gastrointestinal ulcer/bleed, pain, pancreas-related, radiation toxicity) or nonlocal/distant disease (eg, thromboembolic events, cytopenia, dehydration, nausea/vomiting/motility problem, malnutrition and cachexia, ascites, pathologic fracture, and chemotherapy-related toxicity). Competing risk analyses were used to identify predictors of hospitalization.

RESULTS:

Of the total cohort, 9,347 patients (43.5%) were hospitalized for a local complication and 13,101 patients (60.9%) for a nonlocal complication. After adjusting for the competing risk of death, the 12-month cumulative incidence of hospitalization from local complications was highest in patients with unresectable disease (53.1%), followed by resectable (39.5%) and metastatic disease (33.7%) at diagnosis. For nonlocal complications, the 12-month cumulative incidence was highest in patients with metastatic disease (57.0%), followed by unresectable (56.8%) and resectable disease (42.8%) at diagnosis. Multivariable analysis demonstrated several predictors of hospitalization for local and nonlocal complications, including age, race/ethnicity, location of residence, disease stage, tumor size, and diagnosis year. Radiation and chemotherapy had minimal impact on the risk of hospitalization.

CONCLUSIONS:

Despite the widely known predilection of nonlocal/distant disease spread in pancreatic cancer, local tumor progression also leads to substantial morbidity and frequent hospitalization.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas Tipo de estudo: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas Tipo de estudo: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article